← Browse by Condition
Medical Condition
non muscle invasive bladder urothelial carcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for non muscle invasive bladder urothelial carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — non muscle invasive bladder urothelial carcinoma Clinical Trials
How many clinical trials are currently recruiting for non muscle invasive bladder urothelial carcinoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for non muscle invasive bladder urothelial carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for non muscle invasive bladder urothelial carcinoma?
non muscle invasive bladder urothelial carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a non muscle invasive bladder urothelial carcinoma clinical trial?
Eligibility criteria for non muscle invasive bladder urothelial carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 1
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT06770582 Phase 2
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Enrollment
160 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
NCT05483868 Phase 1
Recruiting
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Enrollment
55 pts
Location
United States, Austr...
Sponsor
Aura Biosciences
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology